Paper II
2024 March (Supplementary) (2019 Scheme) · 100 marks · 180 min

Question

Prasad, 40-year-man weighing 60 kg suffering from chronic cough with expectoration and fever was diagnosed to have cavitary pulmonary tuberculosis. (

  • (a) Classify the drugs used in the treatment of tuberculosis. ( 4 mark(s)
  • (b) Discuss in detail on the mechanism of action and adverse effects of first line antitubercular drugs. ( 8 mark(s)
  • (c) Add a note on the drug therapy of Multi Drug Resistant tuberculosis 3 mark(s)
Q215 marksEssays

Answer

a) Classification of antitubercular drugs

LineDrugs
First-lineIsoniazid, Rifampicin, Pyrazinamide, Ethambutol, Streptomycin
Second-lineFluoroquinolones, Aminoglycosides (Kanamycin, Amikacin), Ethionamide, Cycloserine, PAS, Bedaquiline, Linezolid

b) Mechanism of action and adverse effects of first-line drugs

  • Isoniazid — a prodrug, activated by mycobacterial KatG, inhibits InhA (mycolic acid synthesis), bactericidal against actively dividing organisms. AE: peripheral neuropathy (prevented by pyridoxine), hepatotoxicity.
  • Rifampicin — inhibits bacterial RNA polymerase, active against both dividing and semi-dormant organisms. AE: hepatotoxicity, orange-red body fluid discoloration, potent CYP450 induction.
  • Pyrazinamide — active specifically in the acidic intracellular/caseous environment, mechanism incompletely understood. AE: hepatotoxicity, hyperuricemia.
  • Ethambutol — inhibits arabinosyl transferase (arabinogalactan synthesis), bacteriostatic. AE: optic neuritis (dose-related, red-green color blindness — the specific reason visual acuity/color vision monitoring is recommended).
  • Streptomycin — aminoglycoside, inhibits bacterial protein synthesis (30S ribosomal subunit). AE: ototoxicity, nephrotoxicity.

c) Drug therapy of MDR-TB MDR-TB (resistant to at least isoniazid and rifampicin) requires a longer, more toxic second-line regimen combining fluoroquinolones, second-line injectables, and other agents (ethionamide, cycloserine, PAS), often supplemented with newer drugs (bedaquiline, linezolid), for 18-24 months (or shorter regimens where available), with poorer outcomes and greater toxicity than standard therapy.

Other Years Asked


Revise MBBS
Preview